Entities / Company
Novo Nordisk.
Danish pharmaceutical company
- Reports this week
- 7
- Active events
- 4
- Connections
- 561
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported12 reports6 developments inside
-
Novo Nordisk committed $200M to the World Diabetes Foundation (WDF) to strengthen health care in Jordan and Tanzania.Some support3 reports
-
Novo Nordisk and Eric Lawitz presented research results at the AASLD meeting in Denver.Some support1 report
-
Denver hosts the annual MASH meeting, featuring presentations from Novo Nordisk and Gilead Sciences on new therapies.Some support1 report
Earlier this month
-
Novo Nordisk's repurchase program is operating under the regulations of the European Union.Some support3 reports
-
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Well supported18 reports1 development inside
-
Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Well supported3 reports1 development inside
-
Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Well supported5 reports
-
Health Canada regulates the approval of generic pharmaceuticals, allowing market entry following patent expiration.Well supported5 reports2 developments inside
-
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Well supported34 reports6 developments inside
-
Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.Some support1 report
-
Omnicom Group secured new mandates and account extensions from CVS Health, L'Oréal, Mercedes-Benz, and Novo Nordisk.Some support1 report
-
BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Some support1 report
-
Novo Nordisk filed required documents with the SEC regarding stock changes on October 22, 2026.Some support1 report
-
Berenberg Bank reissued a neutral rating on Novo Nordisk shares today.Some support2 reports
-
Ahmad seeks funding from Novo Nordisk while David L. Cohen facilitates talks in Philadelphia, supported by Josh Shapiro's appointment.Some support1 report
-
Personnel changes at Novo Nordisk and Lundbeck, including Mike Doustdar succeeding Lars Fruergaard Jørgensen and proposals for Lundbeck's board.Some support2 reports
-
Novo Nordisk announced its support for India's mission to eliminate Sickle Cell Disease (SCD).Some support5 reports
-
CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Well supported7 reports1 development inside
One to three months ago
-
Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.Some support1 report
-
Aspen Pharmacare began producing insulin for Novo Nordisk under a new manufacturing contract.Some support1 report
-
Novo Nordisk is preparing for the next chapter of its operations in Monksland.Some support1 report1 development inside
-
Novo Nordisk has expanded its base in Athlone, with Tom Quinn serving as VP and Site Head.Some support1 report
-
Michael Yee provided stock views on Novo Nordisk and Eli Lilly on October 8, 2026.Some support1 report
-
Clue and Novo Nordisk have partnered to provide health services.Some support3 reports
-
Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.Some support1 report1 development inside
-
Eli Lilly and Novo Nordisk developed GLP-1 weight-loss drugs, coinciding with operational status changes at SSA offices in New York.Some support1 report
-
Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.Well supported17 reports1 development inside
-
Anthropic is partnering with Novo Nordisk to accelerate new medicine development by utilizing Claude AI.Some support4 reports
-
BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Some support1 report
-
Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Some support1 report
-
Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.Well supported7 reports3 developments inside
-
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Well supported10 reports7 developments inside
-
Novo Nordisk's Wegovy received FDA approval for treating MASH, posing a competitive challenge to Madrigal Pharmaceuticals' Rezdiffra.Well supported3 reports
-
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Well supported29 reports10 developments inside
-
Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Well supported4 reports
-
FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.Well supported4 reports1 development inside
-
Regulatory bodies, including the EMA and FDA, are reviewing evidence regarding semaglutide and its possible association with NAION, a serious eye stroke.Some support2 reports
-
Novo Nordisk CEO Mike Doustdar provided an outlook on the company's market potential.Well supported12 reports
-
Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.Some support1 report1 development inside
-
Novo Nordisk was a major engine of Denmark's growth, but a hiring freeze was raising concerns among policymakers on August 22, 2025.Well supported4 reports
-
Novo Nordisk is undergoing strategic shifts, including rebranding to Novo, appointing a Special Envoy for Health Resilience, and partnering with Cradle for AI-powered protein design.Some support1 report1 development inside
-
KAIMRC signed clinical-trial capability partnership with Novo Nordisk and an AI research partnership with Rutgers University.Some support1 report
-
Novo Nordisk and UNICEF are investing in prevention initiatives, including childhood obesity, across several countries.Some support1 report
-
Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.Some support1 report
-
Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Some support8 reports
-
The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.Some support2 reports
-
OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.Some support2 reports
-
Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.Some support1 report
-
Novo Nordisk is developing an investigational therapy involving CagriSema for the treatment of Type 2 Diabetes and obesity.Some support1 report
-
Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.Well supported4 reports
-
Novo Nordisk's Ozempic sales rely on Health Canada approval and utilize Rexall as the primary market for savings card redemption.Some support1 report
-
A representative made specific stock market transactions on September 19, 2026, involving Novo Nordisk, PepsiCo, and JPMorgan Chase & Co.Some support3 reports
-
Collaboration between Novo Nordisk and Ascendis Pharma terminated regarding TransCon products.Some support2 reports
-
Novo Nordisk is seeking marketing authorization from the European Medicines Agency (EMA).Some support1 report
-
Novo Nordisk expanded its pediatric label franchise on September 15, 2026.Some support1 report
-
Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.Some support1 report
-
Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.Some support1 report
-
Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Some support3 reports
-
Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Novo Nordisk
Events traced to Novo Nordisk, step by step, newest first- CVS Health retaining Caremark and Aetna may affect Novo Nordisk accessCVS Health retaining Caremark and Aetna may affect Novo Nordisk accessPossible
- AGC Biologics' expanded capacity may increase competition for Novo NordiskAGC Biologics' expanded capacity may increase competition for Novo NordiskPossible
- Increased life sciences funding may intensify competition for Novo NordiskIncreased life sciences funding may intensify competition for Novo NordiskPossible
- Novo Nordisk may face pressure from Eli Lilly's growing fund weightNovo Nordisk may face increased competitive pressure from Eli Lilly's market dominancePossible
- Amgen's successful drug trial may increase pressure on Novo NordiskAmgen's successful drug trial may increase competitive pressure on Novo NordiskPossible
- Novo Nordisk may benefit from Regeneron's strengthened financial positionNovo Nordisk may see increased demand for filling services from RegeneronPossible
See all 19 explainers
- Generic semaglutide entry could challenge Novo Nordisk's market shareNovo Nordisk may face reduced revenue from generic semaglutide entry into CanadaPossible
- AI efficiency may lower Novo Nordisk's drug production costsNovo Nordisk may benefit from lower operational costs due to AI-driven QA/QC efficiencyLikely
- Novo Nordisk may benefit from expanding GLP-1 drug marketNovo Nordisk may benefit from expanding GLP-1 drug marketLikely
- Increased competition from QSIVA may challenge Novo Nordisk's market positionIncreased competition from QSIVA may challenge Novo Nordisk's market positionPossible
- Lilly's pipeline expansion intensifies competition for Novo NordiskLilly's pipeline expansion intensifies competition for Novo NordiskLikely
- New AI-engineered protein pipeline may challenge Novo NordiskNew AI-engineered protein pipeline may challenge Novo Nordisk's metabolic market share.Possible
- Novo Nordisk may gain from positive market sentiment on Eli LillyNovo Nordisk may benefit from increased investor confidence in the GLP-1 drug marketPossible
- Defensive capital rotation may lift Novo Nordisk amid Iran war fearsNovo Nordisk may benefit from defensive capital rotation amid Iran war fearsLikely
- Eli Lilly's investor focus may intensify competition for Novo NordiskEli Lilly's increased investor focus may intensify competition for Novo NordiskPossible
- Novo Nordisk may face market pressure from US drug pricing shiftsNovo Nordisk may face market share pressure from US drug pricing policy shiftsPossible
- Novo Nordisk may gain from China's focus on biopharmaNovo Nordisk may benefit from increased biopharmaceutical cooperation with ChinaPossible
- GLP-1 drug findings could boost Novo Nordisk's longevity market appealNovo Nordisk's GLP-1 drugs may expand market focus from weight loss to longevity.Reported
- Novo Nordisk appoints new CEO amid market share challengesNovo Nordisk faces leadership change amid competitive pressure and patent expirationReported
Explainers that pass through Novo Nordisk
Novo Nordisk is a step on the way to someone else- GLP-1 market growth could intensify competitive pressure on PfizerIncreased competition in GLP-1 market may pressure Pfizer's existing drug portfolioPossible
- Viking Therapeutics may face pressure from GLP-1 market expansionViking Therapeutics may face increased competitive pressure from GLP-1 market growthPossible
Around Novo Nordisk this week
News at the entities that move Novo Nordisk most-
Eli Lilly and Company OperationalEli Lilly is building a new facility in Pennsylvania, with Governor Shapiro attending the groundbreaking ceremony.Moves Novo Nordisk
-
European Medicines Agency StructuralForbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.Moves Novo Nordisk
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Novo Nordisk
-
Morgan Stanley TransactionalBaird lowered its price target for Nvidia, Morgan Stanley took it off its Top Pick list, and Jim Cramer predicted shares may not find a low.Moves Novo Nordisk
-
Medicare StructuralIndiana hospital association reports a surge in uncompensated care as lawmakers return to Indianapolis for budget session.Moves Novo Nordisk
-
Donald Trump OperationalDonald Trump appointed Lee Rudofsky, while Google reported a payment to Entergy for a data center setup in Arkansas, amid a judge considering disclosure limits.Moves Novo Nordisk
Connections
The 40 strongest of 561, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mike Doustdar Structural
Mike Doustdar serves as the president and CEO of Novo Nordisk, guiding its strategic direction.
-
Eli Lilly and Company Operational
The two pharmaceutical companies are engaged in intense, high-stakes competition for global market leadership in the obesity and diabetes drug market.
-
Hims & Hers Health Operational
The relationship is a volatile cycle of formal partnership and intense market competition over GLP-1 drugs, frequently shifting due to regulatory and competitive pressures.
-
Filip Knop Structural
Filip Knop serves as the company's Senior Vice President and Chief Medical Officer.
-
Viking Therapeutics Operational
Viking Therapeutics and Novo Nordisk are direct competitors in the global weight loss and obesity drug market.
-
Rosalind Structural
Novo Nordisk integrates Rosalind AI into its Research and Development operations.
-
European Medicines Agency Structural
Novo Nordisk relies on the EMA for market authorization and evaluation of its products.
-
CVS Health Structural
CVS Health and Novo Nordisk maintain a formal, ongoing partnership where CVS distributes and provides retail access to Novo Nordisk's pharmaceutical products.
Show all 40 connections
-
Amgen Operational
Amgen and Novo Nordisk are direct competitors in the GLP-1 and obesity drug markets.
-
FDA Structural
The FDA functions as the mandatory regulatory gatekeeper, controlling market access and product approvals for Novo Nordisk.
-
Denmark Structural
Novo Nordisk is a major Danish company whose operational base and economic success significantly contribute to Denmark's growth and exports.
-
World Diabetes Foundation Transactional
Novo Nordisk has committed a $200 million pledge to the World Diabetes Foundation.
-
Prothena (Ireland) Structural
Novo Nordisk acquired an asset from Prothena and maintains an ongoing operational partnership tied to milestone payments.
-
Washington Operational
Novo Nordisk is localizing its U.S. supply chain in Washington, supported by favorable domestic manufacturing policies.
-
Eric Transactional
Eric led BIOCORP through an acquisition by Novo Nordisk.
-
Anthropic Operational
Anthropic partners with Novo Nordisk to integrate Claude AI into drug research and development workflows.
-
Nvidia Operational
Nvidia and Novo Nordisk maintain an operational partnership where Nvidia provides AI infrastructure and customized models to accelerate Novo Nordisk's drug discovery efforts.
-
Hoffmann-La Roche Operational
Hoffmann-La Roche and Novo Nordisk are direct competitors in the global obesity and weight-loss drug markets.
-
South Africa Operational
Novo Nordisk operates and markets its products in South Africa, subject to local court rulings and market dynamics.
-
Lars Fruergaard Jørgensen Structural
Lars Fruergaard Jørgensen serves as the CEO and leader of Novo Nordisk, with his tenure tied to the company's market performance and clinical advancements.
-
Morgan Stanley Transactional
Morgan Stanley influences Novo Nordisk's market perception through investment stake adjustments and stock rating changes.
-
Medicare Structural
Medicare dictates market access, coverage levels, and pricing structures for Novo Nordisk's pharmaceutical products.
-
Lexicon Pharmaceuticals Structural
Lexicon Pharmaceuticals granted Novo Nordisk an exclusive license for its obesity drug LX9851, which Novo Nordisk develops and commercializes.
-
Regeneron Pharmaceuticals Operational
Novo Nordisk supplies filling services for Regeneron vials while both companies actively compete in the chronic disease management market.
-
Donald Trump Operational
Trump's regulatory demands and political actions directly influence Novo Nordisk's pricing and business operations.
-
AstraZeneca Operational
The two companies are direct, active competitors, specifically challenging each other in the obesity drug market.
-
HSBC Operational
HSBC actively provides financial ratings, price targets, and market analysis on Novo Nordisk's shares.
-
Food and Drug Administration Structural
The FDA formally regulates and approves Novo Nordisk's pharmaceutical products.
-
Aspen Pharmacare Structural
Aspen Pharmacare functions as a contract manufacturer for Novo Nordisk while also pursuing competitive opportunities in the generic semaglutide market.
-
Martin Lange Structural
Martin Lange holds the executive vice president for Development role at Novo Nordisk.
-
Dario Amodei Operational
The partnership between A's company (Anthropic) and Novo Nordisk focuses on leveraging advanced AI capabilities to accelerate drug discovery and improve research outcomes.
-
Lars Jørgensen Structural
Lars Jørgensen held the executive position of CEO at Novo Nordisk.
-
Indiana Transactional
Novo Nordisk supplies GLP-1 medications to support an affordable access program run by the State of Indiana.
-
Camilla Sylvest Structural
Camilla Sylvest was employed by Novo Nordisk for nearly three decades.
-
George Godfrey Structural
George Godfrey was appointed Senior Director at Novo Nordisk, establishing a formal employment dependency.
-
Health Canada Structural
Health Canada serves as the required national regulatory body whose approval dictates market access for Novo Nordisk products in Canada.
-
Bristol-Myers Squibb Operational
The two companies are direct competitors operating within the broader healthcare sector.
-
Novo Nordisk Foundation Structural
The Foundation provides strategic support and shared governance to Novo Nordisk's operations and pipeline.
-
GoodRx Operational
GoodRx and Novo Nordisk collaborate on a partnership where GoodRx distributes Novo Nordisk's GLP-1 products and utilizes its platform for patient access.
-
KAIMRC entered a clinical-trial capability partnership with Novo Nordisk.
History
Events by the month they beganNovember 2026
3 events- Novo Nordisk committed $200M to the World Diabetes Foundation (WDF) to strengthen health care in Jordan and Tanzania.
- Novo Nordisk and Eric Lawitz presented research results at the AASLD meeting in Denver.
- Denver hosts the annual MASH meeting, featuring presentations from Novo Nordisk and Gilead Sciences on new therapies.
October 2026
15 events- Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.
- Omnicom Group secured new mandates and account extensions from CVS Health, L'Oréal, Mercedes-Benz, and Novo Nordisk.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
- Novo Nordisk filed required documents with the SEC regarding stock changes on October 22, 2026.
- Berenberg Bank reissued a neutral rating on Novo Nordisk shares today.
- Ahmad seeks funding from Novo Nordisk while David L. Cohen facilitates talks in Philadelphia, supported by Josh Shapiro's appointment.
- Personnel changes at Novo Nordisk and Lundbeck, including Mike Doustdar succeeding Lars Fruergaard Jørgensen and proposals for Lundbeck's board.
- Novo Nordisk announced its support for India's mission to eliminate Sickle Cell Disease (SCD).
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- Aspen Pharmacare began producing insulin for Novo Nordisk under a new manufacturing contract.
- Novo Nordisk is preparing for the next chapter of its operations in Monksland.
- Novo Nordisk has expanded its base in Athlone, with Tom Quinn serving as VP and Site Head.
- Michael Yee provided stock views on Novo Nordisk and Eli Lilly on October 8, 2026.
- Clue and Novo Nordisk have partnered to provide health services.
- Eli Lilly and Novo Nordisk developed GLP-1 weight-loss drugs, coinciding with operational status changes at SSA offices in New York.
September 2026
27 events- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly and Novo Nordisk are pivoting their product descriptions toward longevity therapeutics and have backed a funding round for an epigenetic reprogramming company.
- Anthropic is partnering with Novo Nordisk to accelerate new medicine development by utilizing Claude AI.
- BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.
- Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Regulatory bodies, including the EMA and FDA, are reviewing evidence regarding semaglutide and its possible association with NAION, a serious eye stroke.
- Hoffmann-La Roche and Novo Nordisk are competing in the global obesity drug market, with stock trading occurring in Zurich.
- Novo Nordisk is undergoing strategic shifts, including rebranding to Novo, appointing a Special Envoy for Health Resilience, and partnering with Cradle for AI-powered protein design.
- KAIMRC signed clinical-trial capability partnership with Novo Nordisk and an AI research partnership with Rutgers University.
- Novo Nordisk and UNICEF are investing in prevention initiatives, including childhood obesity, across several countries.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- The FDA has granted market exclusivity for certain drugs, while analysts are comparing Novo Nordisk's development phase to AI rollouts, amidst concerns over patent cliffs.
- OpenAI and Anthropic announced a partnership to use Claude models in R&D, while Novo Nordisk and Eli Lilly intensify competition in the obesity drug market.
- Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.
- Novo Nordisk is developing an investigational therapy involving CagriSema for the treatment of Type 2 Diabetes and obesity.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
- Novo Nordisk's Ozempic sales rely on Health Canada approval and utilize Rexall as the primary market for savings card redemption.
- A representative made specific stock market transactions on September 19, 2026, involving Novo Nordisk, PepsiCo, and JPMorgan Chase & Co.
- Collaboration between Novo Nordisk and Ascendis Pharma terminated regarding TransCon products.
- Novo Nordisk is seeking marketing authorization from the European Medicines Agency (EMA).
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
- Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.
- Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.
Show 3 earlier months
August 2026
2 eventsJuly 2026
1 eventJune 2026
12 events- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Health Canada regulates the approval of generic pharmaceuticals, allowing market entry following patent expiration.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Novo Nordisk's Wegovy received FDA approval for treating MASH, posing a competitive challenge to Madrigal Pharmaceuticals' Rezdiffra.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.
- Novo Nordisk was a major engine of Denmark's growth, but a hiring freeze was raising concerns among policymakers on August 22, 2025.